Related references
Note: Only part of the references are listed.Macrophage-derived CCL5 facilitates immune escape of colorectal cancer cells via the p65/STAT3-CSN5-PD-L1 pathway
Chao Liu et al.
CELL DEATH AND DIFFERENTIATION (2020)
Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours
Han Yao et al.
NATURE BIOMEDICAL ENGINEERING (2019)
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
Mauro Poggio et al.
CELL (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity
Xing Huang et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Palmitoylation stabilizes PD-L1 to promote breast tumor growth
Yi Yang et al.
CELL RESEARCH (2019)
Blocking PD-L1 for anti-liver cancer immunity: USP22 represents a critical cotarget
Xing Huang et al.
Cellular & Molecular Immunology (2019)
HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity
Huanbin Wang et al.
NATURE CHEMICAL BIOLOGY (2019)
Small-Molecule Sigma1 Modulator Induces Autophagic Degradation of PD-L1
Christina M. Maher et al.
MOLECULAR CANCER RESEARCH (2018)
Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance
Jinfang Zhang et al.
NATURE (2018)
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Chia-Wei Li et al.
CANCER CELL (2018)
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
Jong-Ho Cha et al.
MOLECULAR CELL (2018)
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen et al.
NATURE (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells
Victoria J. Gennaro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer
Xiaohui Zhang et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2017)
PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma
V. Atsaves et al.
LEUKEMIA (2017)
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
Riccardo Mezzadra et al.
NATURE (2017)
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Marian L. Burr et al.
NATURE (2017)
A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma
Paolo D'Arrigo et al.
Oncotarget (2017)
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Zijun Y. Xu-Monette et al.
FRONTIERS IN IMMUNOLOGY (2017)
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Sherene Loi et al.
CLINICAL CANCER RESEARCH (2016)
PDL1 Regulation by p53 via miR-34
Maria Angelica Cortez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
PDL1 Regulation by p53 via miR-34
Maria Angelica Cortez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Deubiquitination and Stabilization of PD-L1 by CSN5
Seung-Oe Lim et al.
CANCER CELL (2016)
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey J. Langer et al.
LANCET ONCOLOGY (2016)
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Chia-Wei Li et al.
NATURE COMMUNICATIONS (2016)
CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway
Qiuyuan Wen et al.
ONCOTARGET (2016)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB
Kavitha Gowrishankar et al.
PLOS ONE (2015)
USP22 Regulates Oncogenic Signaling Pathways to Drive Lethal Cancer Progression
Randy S. Schrecengost et al.
CANCER RESEARCH (2014)
PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation
Muhammad Zaeem Noman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer
Minmin Song et al.
PLOS ONE (2013)
The Ubiquitin Code
David Komander et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 81 (2012)
USP22 Antagonizes p53 Transcriptional Activation by Deubiquitinating Sirt1 to Suppress Cell Apoptosis and Is Required for Mouse Embryonic Development
Zhenghong Lin et al.
MOLECULAR CELL (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
USP22 Is Useful as a Novel Molecular Marker for Predicting Disease Progression and Patient Prognosis of Oral Squamous Cell Carcinoma
Songlin Piao et al.
PLOS ONE (2012)
USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1
Boyko S. Atanassov et al.
EMBO REPORTS (2011)
Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer
Youxue Zhang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
Paclitaxel Induced B7-H1 Expression in Cancer Cells via the MAPK Pathway
Wenrong Gong et al.
JOURNAL OF CHEMOTHERAPY (2011)
Gcn5 and SAGA Regulate Shelterin Protein Turnover and Telomere Maintenance
Boyko S. Atanassov et al.
MOLECULAR CELL (2009)
Breaking the chains: structure and function of the deubiquitinases
David Komander et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression
Xiao-Yong Zhang et al.
MOLECULAR CELL (2008)
Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis
Ping Zhang et al.
MOLECULAR IMMUNOLOGY (2008)
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway
Jizhong Liu et al.
BLOOD (2007)
Certain pairs of ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases (E3s) synthesize nondegradable forked ubiquitin chains containing all possible isopeptide linkages
Hyoung Tae Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Jab1 induces the cytoplasmic localization and degradation of p53 in coordination with Hdm2
Wonkyung Oh et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
The deubiquitylation activity of Ubp8 is dependent upon Scf11 and its association with the SAGA complex
KK Lee et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of Nedd8 from Cul1
GA Cope et al.
SCIENCE (2002)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
Jab1 antagonizes TGF-β signaling by inducing Smad4 degradation
M Wan et al.
EMBO REPORTS (2002)
The cytoplasmic shuttling and subsequent degradation of p27Kip1 mediated by Jab1/CSN5 and the COP9 signalosome complex
K Tomoda et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
